First-in-human trial of Capricor’s StealthX™ vaccine initiated under HHS’s Project NextGenTrial conducted and funded by the ...

Good afternoon, ladies and gentlemen, and welcome to the Capricor Therapeutics Second Quarter 2025 Conference Call. [Operator Instructions] This call is being recorded on Monday, August 11, 2025. I ...

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit ...

Despite zero revenue and increased losses, Capricor Therapeutics Inc (CAPR) focuses on strategic initiatives and regulatory ...

Company to Host Conference Call on August 13, 2025, at 4:30 p.m. ET –SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Capricor ...

Capricor Therapeutics, Inc. (CAPR) is scheduled to announce Q2 earnings results on Wednesday, August 13th, after market close. The consensus EPS Estimate is -$0 ...

Capricor Therapeutics Inc. CAPR) on Monday reported a loss of $25.9 million in its second quarter. On a per-share basis, the ...

NEW YORK - August 12, 2025 ( NEWMEDIAWIRE) - Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of a class action securities lawsuit.

Detailed price information for Capricor Therap (CAPR-Q) from The Globe and Mail including charting and trades.

Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases.

Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPRLOS ANGELES-- (BUSINESS WIRE)--Centene Corporation Investigated for ...